Golotimod TFA (SCV 07 TFA) 一种具有抗菌活性的免疫调节肽，可显着提高抗结核治疗的功效，刺激胸腺和脾细胞增殖，并改善巨噬细胞功能。Golotimod TFA (SCV 07 TFA) 抑制 STAT3 信号传导并调节接受放疗或放疗与顺铂联合用药的动物模型中口腔粘膜炎的持续时间和严重程度。Golotimod TFA (SCV 07 TFA) 是复发性生殖器单纯疱疹病毒 2 型 (HSV-2) 的潜在治疗药物。
货号:ajcx13922
CAS:N/A
分子式:C18H20F3N3O7
分子量：447.36
溶解度:Soluble in DMSO
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod TFA (SCV 07 TFA) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod TFA (SCV 07 TFA) is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3]. STAT3[2]

[1]. Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents. 2008 Sep;32(3):262-6. [2]. Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92. [3]. Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis. 2010 Oct;16(7):655-60.